However, it has been reported that PHT could develop before the onset of cirrhosis in a subset of cases, (2) suggesting that PHT could be related in these cases to a noncirrhotic PHT rather than to extensive fibrosis or cirrhosis. (3) In line with this hypothesis, we describe here the clinical, imaging, and liver pathology features of 10 patients who underwent a liver transplantation (LT) for CFLD with PHT. We demonstrate that, in 8 patients, PHT is due to a noncirrhotic PHT and diffuse obliterative portal venopathy (OPV).
Patients and Methods
Between 2011 and 2017, 10 adults underwent LT for CFLD at a single center. All patients had PHT and were evaluated by computed tomography (CT) scan (9 patients) or magnetic resonance (1 patient) and endoscopy. Nine patients had end-stage pulmonary disease with indication of lung transplantation. LT per se was not required in most patients, but the risk of decompensation of PHT during or after lung transplantation was considered high enough to justify a combined lung transplantation and LT. One woman underwent LT only for cirrhosis with refractory ascites.
The delay between imaging procedures and LT was 10 days to 18 months (median, 2 months). Prothrombotic disorder evaluation was performed as previously described. (4) Liver explants were examined by 2 experienced hepatic pathologists (D.C.H., V.P.) on at least 10 representative sections.
Results
Clinical, biochemical, and imaging characteristics of the patients are summarized in Table 1 . All patients had portal-systemic circulation; 9 had grade 2-3 esophageal varices, but none had variceal bleeding. Prothrombotic disorder evaluation was performed in 7 patients and was normal.
Abbreviations: APRI score, aspartate aminotransferase to platelet ratio index; AST, aspartate aminotransferase; BMI, body mass index; CF, cystic fibrosis; CFLD, cystic fibrosis liver disease; CFTR, cystic fibrosis transmembrane conductance regulator; CT, computed tomography; INCPH, idiopathic noncirrhotic portal hypertension; IQR, interquartile range; ISC, incomplete septal cirrhosis; LT, liver transplantation; MELD, Model for End-Stage Liver Disease; NA, not available; OPV, obliterative portal venopathy; PAS, periodic acid-Schiff; PHT, portal hypertension. 
IMAGING
Portal veins were patent in 9 patients. The main portal vein was dilated in all the patients (range, 14-30 mm). One patient had nonocclusive thrombosis of the left portal branch. Mural calcifications of portal or collateral veins were found in 3 patients (Fig.  1A,B) . The intrahepatic portal branches were abnormal in 9 patients (thrombosis, reduction in caliber, and/or nonvisibility). The liver was dysmorphic in all cases, mainly related to right liver atrophy (7 patients) and hypertrophy of segment 4 (4 patients).
The liver surface was nodular and irregular in 5 patients. All patients had splenomegaly (range, 19-30 cm; median, 23 cm) and large portal-systemic collaterals (Fig. 1A) .
PATHOLOGY
Pathological findings of the 10 liver explants are summarized in Table 1 . At macroscopic examination, 2 livers had a smooth, regular surface (Fig. 1C) . At cross section, there was evidence of cirrhosis, incomplete septal cirrhosis (ISC), and macronodular regeneration in 2, 5, and 3 livers, respectively (Fig. 1D) . In 1 cirrhotic liver, 5 nodules measuring 6-15 mm were present. Histological examination showed features of idiopathic noncirrhotic PHT in 8 noncirrhotic livers, with grade 2 fibrosis (Fig. 1E ) or focally grade 3 in 5 livers. Diffuse nodular regeneration and thin portal septa without permeable portal veins were observed (Fig.  1F,G) . Large portal veins were permeable, sometimes surrounded by multiple small vascular channels suggesting intrahepatic cavernous transformation. Sinusoidal dilatation was minimal, without congestion. Largeand medium-size bile ducts were normal. No mucous deposits or cholangitis were seen. Scarce periodic acidSchiff (PAS)-positive plugs were present in ductules around portal tracts in all livers.
Livers with cirrhosis (n 5 2) showed features of biliary cirrhosis with multiple PAS-positive plugs in bile ductules. Large-and medium-size bile ducts were normal, without cholangitis or cholestasis. Only 1 of the 5 nodules observed in a patient with cirrhosis was dysplastic high grade.
Discussion
In this well-characterized series of 10 adults with CFLD and PHT, we have demonstrated by examination of the entire liver that a majority of patients (8/10) had noncirrhotic PHT. The 2 patients with cirrhosis had biliary cirrhosis as described in pediatric patients. The present cohort is small but represents approximately one-third of the LT patients with CF and PH during the same period in France.
Patients without cirrhosis had intrahepatic PHT highlighted by the following:
1. Persistent clinical splenomegaly confirmed by imaging (19-30 cm) with portal vein dilatation (range, 14-28 mm; median, 21 mm) and thrombocytopenia in 9 patients. 2. Endoscopic esophageal varices in 9 of 10 patients. 3. Portal-systemic venous collaterals visualized by CT scan. 4. Permeable portal and hepatic veins as assessed by imaging and macroscopic examination.
Our results are in line with a previous study reporting, in a series of 9 children with CF and PHT, where only 2 had well-characterized cirrhosis. (3) Our data demonstrate that PHT may develop independently of extensive fibrosis or cirrhosis. Accordingly, we postulate that patients with CF and PHT without cirrhosis may have idiopathic noncirrhotic portal hypertension (INCPH), as proposed by Witters et al. (3) INCPH, or intrahepatic PH without cirrhosis, has been defined as a disease of uncertain etiology characterized by periportal fibrosis and involvement of small and medium branches of the portal vein, resulting in development of PHT. Recent morphologic studies have clearly shown that INCPH includes a wide spectrum of histological lesions. (4) This explains why various names have been used in the past to designate this entity, such as hepatoportal sclerosis, nodular regenerative hyperplasia, ISC, partial nodular transformation, noncirrhotic portal fibrosis, and benign intrahepatic PHT. It is now believed that these terms represent temporal and spatial heterogeneity of a single condition whose underlying pathogenesis is OPV. Indeed, in our series, all patients without cirrhosis displayed features of OPV, such as obliterated portal veins with a thick muscular wall, or, in some portal tracts, absence of portal veins. The hepatic venous pressure gradient was measured by transjugular catheterization in 2 patients and was low in 1 (6 mm Hg). This contrasts with the observation of grade II esophageal varices and radiologically significant PHT and is characteristic of INCPH. (5) Severe PH is related to both structural (fibrosis) and LIVER TRANSPLANTATION, Vol. 23, No. 10, 2017 HILLAIRE ET AL.
functional components (intrahepatic resistance, elevated portal blood flow). In 4 patients without cirrhosis of our series, the high liver elasticity (19-73 kPa) was not correlated to fibrosis (mainly graded F2). In these patients, increase of portal venous inflow and intrahepatic vascular tone could play an important role in development of PH. Because patients with CFLD usually have a wellpreserved liver function, a major problem is to determine whether LT is indicated when lung transplantation is required. Indeed, sepsis, renal insufficiency, shock, and hypoxemia may complicate lung transplantation and thereby trigger liver disease decompensation. This is why LT was performed at the time of lung transplantation in 9 of our patients, although it was not indicated on the basis of liver criteria.
The pathogenesis of INCPH is still speculative. The potential mechanisms involved have been classified in 5 main categories: immunological disorders; chronic infections, in particular intestinal infections; exposure to drugs and toxins; a few genetic diseases; and prothrombotic conditions. (5) We expect that 3 factors may play a role in the development of INCPH in CF patients. One could be thrombosis of distal portal branches as a result of platelet activation, because platelets are hyperactive in CF patients. In addition, CF is associated with a rise in markers of vasculitis, and primary endothelialitis could favor portal venules thrombosis. The second factor could be a prothrombic state. In a recent study involving more than 100 patients with CF, thrombophilia abnormalities, or hypercoagulability were found in 50% of the cohort. (6) As a matter of fact, we did not observe any thrombophilic disorders in 7 screened patients from our series. The third factor could be repeated pulmonary infections and intestinal infections. Indeed, repeated infections are frequent in CF patients. Data indicate that, in INCPH, intestinal infections with Escherichia coli might cause recurrent septic embolization and subsequent obstruction of small portal veins. The high prevalence of INCPH in low socioeconomic areas with a high rate of intestinal infections is also consistent with this hypothesis, and experimental studies have shown that Escherichia coli injection into the portal vein resulted in the development of INCPH. Small intestinal bacterial overgrowth is observed in CF. It is therefore likely that gut-derived toxins and microbial products enter the liver through the portal circulation. In addition, changes in the enteric microbiota have been observed in a mouse model of CF and can also lead to a release of proinflammatory cytokines. Altogether, septic embolization of small portal veins, translocation of bacteria and bacterial products, vasculitis, platelet activation, thrombophilia, and hypercoagulability might result in the obstruction of small portal veins and subsequent OPV.
In summary, we propose that in adult patients with CF when cirrhosis is absent, PHT is likely due to INCPH, a consequence of OPV. In such cases, CFLD may be considered as a vascular disease rather than a biliary disease. 
